Similar articles

• In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.

  Fulton RJ, Uhr JW, Vitetta ES. Fulton RJ, et al. Cancer Res. 1988 May 1;48(9):2626-31. Cancer Res. 1988. PMID: 3258547
• Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.

  Fulton RJ, Tucker TF, Vitetta ES, Uhr JW. Fulton RJ, et al. Cancer Res. 1988 May 1;48(9):2618-25. Cancer Res. 1988. PMID: 3258546
• Immunotoxin therapy of hematological malignancies.

  Pasqualucci L, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Bigerna B, Falini B. Pasqualucci L, et al. Haematologica. 1995 Nov-Dec;80(6):546-56. Haematologica. 1995. PMID: 8647523 Review. No abstract available.
• Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.

  Derocq JM, Casellas P, Laurent G, Ravel S, Vidal H, Jansen F. Derocq JM, et al. J Immunol. 1988 Oct 15;141(8):2837-43. J Immunol. 1988. PMID: 3262669
• Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.

  Smyth MJ, Pietersz GA, Farquhar I, McKenzie C. Smyth MJ, et al. Targeted Diagn Ther. 1988;1:123-56. Targeted Diagn Ther. 1988. PMID: 2979055 Review. No abstract available.